Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -43.64% is 25% above its 5-year average of -58.49%, around the middle of its 5-year range (-124.35%–12.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 25.10% below its 12-month average of -34.89%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -43.64%.
RETURN ON EQUITY (ROE)
-43.64%
RETURN ON EQUITY (ROE) AVG TTM
-34.89%
RETURN ON EQUITY (ROE) AVG 3Y
-53.47%
RETURN ON EQUITY (ROE) AVG 5Y
-58.49%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-25.10%
CURRENT VS 3Y AVG
+18.38%
CURRENT VS 5Y AVG
+25.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-3.88%
vs the sector median at left
Whitehawk Therapeutics Inc
Market Cap
$205.80M
Return on Equity (ROE)
-43.64%
TTM Avg
-34.89%
3Y Avg
-53.47%
5Y Avg
-58.49%
Market Cap
$207.27M
Return on Equity (ROE)
28.68%
TTM Avg
26.59%
3Y Avg
20.62%
5Y Avg
19.74%
Market Cap
$208.31M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$209.91M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$210.41M
Return on Equity (ROE)
-71.02%
TTM Avg
-15.82%
3Y Avg
-19.73%
5Y Avg
-5.35%
Market Cap
$200.96M
Return on Equity (ROE)
N/A
TTM Avg
-280.12%
3Y Avg
-179.90%
5Y Avg
-133.80%
Market Cap
$210.98M
Return on Equity (ROE)
-106.27%
TTM Avg
-100.08%
3Y Avg
-64.49%
5Y Avg
-52.22%
Market Cap
$198.33M
Return on Equity (ROE)
N/A
TTM Avg
620.74%
3Y Avg
332.27%
5Y Avg
266.26%
Market Cap
$197.87M
Return on Equity (ROE)
-154.90%
TTM Avg
-136.39%
3Y Avg
-122.19%
5Y Avg
-93.38%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Whitehawk Therapeutics Inc (WHWK) | $205.80M | -43.64% | -34.89% | -53.47% | -58.49% |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 28.68% | 26.59% | 20.62% | 19.74% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | 39.66% | 4.24% | -15.88% | -20.06% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -71.02% | -15.82% | -19.73% | -5.35% |
| Alector, Inc. (ALEC)vs › | $200.96M | N/A | -280.12% | -179.90% | -133.80% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -106.27% | -100.08% | -64.49% | -52.22% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | N/A | 620.74% | 332.27% | 266.26% |
| Exagen Inc. (XGN)vs › | $197.87M | -154.90% | -136.39% | -122.19% | -93.38% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 19.38% | 20.63% | -8.44% | -40.10% |
ROE
-43.6%
ROA
-41.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -43.64% |
| 2026-03-31 | -99.68% |
| 2025-12-31 | -15.11% |
| 2025-09-30 | -9.94% |
| 2025-06-30 | -6.05% |
| 2025-03-31 | 12.45% |
| 2024-12-31 | -121.37% |
| 2024-09-30 | -89.57% |
| 2024-06-30 | -83.06% |
| 2024-03-31 | -76.09% |
| 2023-12-31 | -62.52% |
| 2023-09-30 | -53.65% |
| 2023-06-30 | -46.86% |
| 2023-03-31 | -42.39% |
| 2022-12-31 | -38.21% |
| 2022-09-30 | -37.01% |
| 2022-06-30 | -124.35% |
| 2022-03-31 | -95.06% |
| 2021-12-31 | -80.71% |
| 2021-09-30 | -57.03% |
